Key result
Copeptin concentrations were significantly higher in patients with confirmed ACS compared to those without (median 7.42 vs 3.40 pmol/l, p=0.02), but did not correlate with obstructive CAD on CTA.
Why the study?
Does copeptin measurement at arrival accurately identify acute coronary syndrome and correlate with obstructive coronary artery disease on coronary CTA in patients with suspected ACS?
Cross-Sectional (n=65)
Does copeptin measurement at arrival accurately identify acute coronary syndrome and correlate with obstructive coronary artery disease on coronary CTA in patients with suspected ACS?
Copeptin levels at presentation are elevated in patients with acute coronary syndrome but do not correlate strongly with the presence of obstructive coronary artery disease on CT angiography.
May support early ACS identification in suspected cases; leaves open correlation with obstructive CAD on CTA.
OBJECTIVE: To determine the diagnostic accuracy of copeptin in patients with suspected acute coronary syndrome (ACS) and its correlation with obstructive coronary artery disease (CAD) on coronary CT angiography (CTA). METHODS: Copeptin was measured at arrival in 65 consecutive patients (56 ± 10 years, 45 men) suspected of ACS and no indication for immediate invasive angiography. All patients underwent coronary CTA without disclosure of the results to the treating physician, and outcomes were classified as obstructive CAD (>50% stenosis) or no obstructive CAD (≤ 50%) in one or more vessel. RESULTS: The final diagnosis of ACS was established in 10 (15%) patients, 6 myocardial infarctions and 4 unstable angina pectoris. Coronary CTA detected obstructive CAD in all patients with ACS and in 10 (15%) patients with no ACS. Copeptin concentrations were higher in patients with ACS (median 7.42 pmol/l (IQR 3.71-18.72)) vs patients with no ACS (3.40 pmol/l (1.13-6.27), p=0.02). Copeptin was not higher in patients with obstructive CAD on coronary CTA (4.87 pmol/l (2.90-8.51) vs 3.60 pmol/l (1.21-6.23), p=0.20) compared with patients with no obstructive CAD. CONCLUSIONS: Copeptin seems to be elevated in patients with ACS while there is no strong correlation with obstructive coronary disease on CTA.
No takes yet. Share an insight, caveat, or question.
Dedic et al. (2012) conducted a cross-sectional in Suspected acute coronary syndrome (ACS) (n=65). Copeptin vs. Patients without ACS was evaluated on Diagnosis of ACS (p=0.02). Copeptin concentrations were significantly higher in patients with confirmed ACS compared to those without (median 7.42 vs 3.40 pmol/l, p=0.02), but did not correlate with obstructive CAD on CTA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: